author-photo

Jaya Sangodkar

Icahn School of Medicine at Mount Sinai

32

Papers

918

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma

2019 JCI insight
Show All
- Source
- Cite
- Save
Citations (20)
Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (39)
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

2018 Science Translational Medicine
Show All
- Source
- Cite
- Save
Citations (67)
Abstract 4173: Drug target mutations as a mechanism of acquired resistance to small molecules activators of protein phosphatase 2a

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator

2017 Proteomics
Show All
- Source
- Cite
- Save
Citations (15)
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth

2017 Journal of Clinical Investigation
Show All
- Source
- Cite
- Save
Citations (103)
Abstract 3865: Therapeutic activation of protein phosphatase 2A for the treatment of lung cancer

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Reengineered tricyclic anti-cancer agents.

2015 Bioorganic & Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (35)
Erratum: Reengineered tricyclic anti-cancer agents (Bioorg. Med. Chem. (2015) 23(6528-6534))

2015 Bioorganic & Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (0)
CorrigendumCorrigendum to “Reengineered tricyclic anti-cancer agents” [Bioorg. Med. Chem. 23 (2015) 6528–6534]

2015 Bioorganic & Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (0)